VIVANZA

Vivanza Biosciences financials

Market cap
₹8 Cr

Quarterly results

Q1 FY27: revenue up 3.9%, net profit up 66.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue3 2 0 9 55 +1745%45 +2917%6 +1225%9 +4%
EBITDA0 0 -1 0 1 +455%0 +62%-0 +76%-0 −147%
Net profit0 0 -1 0 1 +2700%0 +400%-0 +55%0 +67%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −8.7% 1Y

₹1.80₹2.00₹2.20₹2.40₹2.60Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹2.06 on 9 Sept 2025 → ₹1.88. High ₹2.61 (14 Nov 2025), low ₹1.7 (11 Jun 2026).

Financials, as filed

Revenue grew 104.1% a year over 2 years, FY24 to FY26. Operating margin narrowed to 0.6%.

Year endingFY24FY25FY26
Revenue₹28 Cr₹7 Cr₹116 Cr
Operating profit₹1 Cr₹-0 Cr₹1 Cr
Operating margin3.8%-4.9%0.6%
Interest₹0 Cr₹0 Cr₹0 Cr
Depreciation₹0 Cr₹0 Cr₹0 Cr
Net profit₹1 Cr₹-1 Cr₹0 Cr
Net margin2.0%-9.0%0.3%
Cash from operations₹2 Cr₹-2 Cr₹-3 Cr
Free cash flow₹2 Cr₹-3 Cr₹-3 Cr
ROCE10.0%-3.0%6.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr
Reserves₹-1 Cr₹-1 Cr₹0 Cr₹1 Cr₹1 Cr₹0 Cr
Borrowings₹0 Cr₹6 Cr₹8 Cr₹5 Cr₹10 Cr₹10 Cr
Other liabilities₹5 Cr₹7 Cr₹10 Cr₹10 Cr₹35 Cr₹8 Cr
Total liabilities₹8 Cr₹16 Cr₹22 Cr₹20 Cr₹50 Cr₹22 Cr
Fixed assets₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹6 Cr₹13 Cr₹20 Cr₹17 Cr₹47 Cr₹20 Cr
Total assets₹8 Cr₹16 Cr₹22 Cr₹20 Cr₹50 Cr₹22 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

The ownership split has held steady since Jun 2025. The shareholder count shrank 6% to 19,254.

Promoters
20.0%
Public
80.0%

Since Jun 2025

  • Promoters 0.00 pp
  • Public 0.00 pp

How it drifted, 12 quarters

Over this window the public went from 52.7% to 80.0% — +27.3 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 47.3%, Public 52.7%.Dec '23: Promoters 44.9%, Public 55.1%.Mar '24: Promoters 43.2%, Public 56.8%.Jun '24: Promoters 40.0%, Public 60.0%.Sep '24: Promoters 39.9%, Public 60.1%.Dec '24: Promoters 20.0%, Public 80.0%.Mar '25: Promoters 20.0%, Public 80.0%.Jun '25: Promoters 20.0%, Public 80.0%.Sep '25: Promoters 20.0%, Public 80.0%.Dec '25: Promoters 20.0%, Public 80.0%.Mar '26: Promoters 20.0%, Public 80.0%.Jun '26: Promoters 20.0%, Public 80.0%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Vivanza Biosciences Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Parth Hemant Parikh 19.77%unchanged
Ravinder Singh 1.70%+0.20 pp
Prashant Tyagi 1.51%unchanged
Manu Narang 1.44%+0.13 pp
Hemant Amrish Parikh 0.25%unchanged
Ashoka Metcast Limited —off the list

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Vivanza Biosciences Limited

Guides on how to read this kind of business and the numbers that matter.